Gallacher Capital Management LLC Reduces Stock Holdings in Astrazeneca Plc $AZN

Gallacher Capital Management LLC trimmed its position in shares of Astrazeneca Plc (NYSE:AZN) by 50.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,043 shares of the company’s stock after selling 4,050 shares during the period. Gallacher Capital Management LLC’s holdings in Astrazeneca were worth $797,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of the company. Mascoma Wealth Management LLC bought a new stake in Astrazeneca in the 1st quarter valued at about $26,000. MV Capital Management Inc. bought a new position in Astrazeneca during the fourth quarter worth about $26,000. Reflection Asset Management purchased a new position in shares of Astrazeneca in the fourth quarter worth about $31,000. Raleigh Capital Management Inc. purchased a new position in shares of Astrazeneca in the first quarter worth about $38,000. Finally, Avion Wealth raised its position in shares of Astrazeneca by 166.2% in the first quarter. Avion Wealth now owns 197 shares of the company’s stock valued at $38,000 after purchasing an additional 123 shares during the period. 20.35% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on AZN. UBS Group restated a “buy” rating on shares of Astrazeneca in a research note on Friday, April 10th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a report on Tuesday, June 30th. Sanford C. Bernstein restated a “buy” rating on shares of Astrazeneca in a research report on Monday, May 4th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a report on Friday, June 26th. Finally, Morgan Stanley reiterated an “overweight” rating on shares of Astrazeneca in a research report on Wednesday, April 8th. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Astrazeneca currently has an average rating of “Moderate Buy” and an average price target of $211.00.

Astrazeneca Stock Up 0.4%

AZN opened at $169.08 on Friday. The company has a fifty day moving average price of $182.44 and a 200-day moving average price of $188.47. The firm has a market capitalization of $262.23 billion, a P/E ratio of 25.39, a price-to-earnings-growth ratio of 1.37 and a beta of 0.24. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. Astrazeneca Plc has a one year low of $137.23 and a one year high of $212.71.

Astrazeneca (NYSE:AZN) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. The company had revenue of $15.29 billion for the quarter, compared to the consensus estimate of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. Equities research analysts expect that Astrazeneca Plc will post 10.26 earnings per share for the current fiscal year.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.